Fluid Biomarker Changes After Amyloid-β-Targeting Drugs

JAMA Neurol. 2024 Jun 1;81(6):579-581. doi: 10.1001/jamaneurol.2024.1103.

Authors

Rik Ossenkoppele^{1

2

3}, Charlotte E Teunissen^{2

4}

Affiliations

¹ Neurology, Alzheimer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
² Neurodegeneration, Amsterdam Neuroscience, Amsterdam, the Netherlands.
³ Clinical Memory Research Unit, Lund University, Lund, Sweden.
⁴ Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

PMID: 38683615
DOI: 10.1001/jamaneurol.2024.1103

No abstract available

MeSH terms

Aged
Alzheimer Disease* / drug therapy
Alzheimer Disease* / metabolism
Amyloid beta-Peptides* / metabolism
Aniline Compounds
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Biomarkers* / metabolism
Ethylene Glycols
Female
Humans
Male
Peptide Fragments / metabolism

Substances

Amyloid beta-Peptides
Biomarkers
Antibodies, Monoclonal, Humanized
aducanumab
Aniline Compounds
florbetapir
Peptide Fragments
Ethylene Glycols